CIK 0001743881 · Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,563,798
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,563,798. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-13 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −9,759 | $69.23 | $676K | 4,438,447 |
| 2026-03-12 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −14,337 | $68.48 | $982K | 661,349 |
| 2026-03-12 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −5,363 | $69.32 | $372K | 655,986 |
| 2026-03-12 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −300 | $70.15 | $21K | 655,686 |
| 2026-03-12 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −13,885 | $68.47 | $951K | 4,464,562 |
| 2026-03-12 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −5,815 | $69.29 | $403K | 4,458,747 |
| 2026-03-12 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −300 | $70.15 | $21K | 4,458,447 |
| 2026-03-10 | Valantine Hannah Director | Option exercise 10b5-1 | +8,671 | $27.36 | $237K | 16,136 |
| 2026-03-10 | Valantine Hannah Director | Sale 10b5-1 | −8,671 | $72.00 | $624K | 7,465 |
| 2026-03-10 | Valantine Hannah Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,671 | 17,343 | ||
| 2026-03-04 | Ellis Andrea Director | Option exercise 10b5-1 | +64,921 | $8.45 | $549K | 83,510 |
| 2026-03-04 | Ellis Andrea Director | Sale 10b5-1 | −64,921 | $64.87 | $4.2M | 18,589 |
| 2026-03-04 | Ellis Andrea Director | Option exercise · Stock Option (right to buy) 10b5-1 | −64,921 | 0 | ||
| 2026-02-27 | Valantine Hannah Director | Option exercise 10b5-1 | +25,484 | $48.45 | $1.2M | 32,949 |
| 2026-02-27 | Valantine Hannah Director | Sale 10b5-1 | −14,584 | $67.08 | $978K | 18,365 |
| 2026-02-27 | Valantine Hannah Director | Sale 10b5-1 | −10,900 | $67.84 | $739K | 7,465 |
| 2026-02-27 | Valantine Hannah Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,484 | 0 | ||
| 2026-02-26 | Apuli Maricel Chief Accounting Officer | Sale 10b5-1 | −2,000 | $66.00 | $132K | 121,945 |
| 2026-02-19 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −18,923 | $71.03 | $1.3M | 243,581 |
| 2026-02-19 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −8,528 | $72.08 | $615K | 235,053 |
Page 8 of 19 · 373 trades